The cost-effectiveness of using pneumococcal conjugate vaccine (PCV13) versus pneumococcal polysaccharide vaccine (PPSV23), in South African adults.

MLA

Feldman, Charles, et al. “The Cost-Effectiveness of Using Pneumococcal Conjugate Vaccine (PCV13) versus Pneumococcal Polysaccharide Vaccine (PPSV23), in South African Adults.” PLoS ONE, vol. 15, no. 1, Jan. 2020, pp. 1–49. EBSCOhost, https://doi.org/10.1371/journal.pone.0227945.

APA

Feldman, C., Dlamini, S. K., Madhi, S. A., Meiring, S., von Gottberg, A., de Beer, J. C., de Necker, M., & Stander, M. P. (2020). The cost-effectiveness of using pneumococcal conjugate vaccine (PCV13) versus pneumococcal polysaccharide vaccine (PPSV23), in South African adults. PLoS ONE, 15(1), 1–49. https://doi.org/10.1371/journal.pone.0227945

Chicago

Feldman, Charles, Sipho K. Dlamini, Shabir A. Madhi, Susan Meiring, Anne von Gottberg, Janetta C. de Beer, Margreet de Necker, and Marthinus P. Stander. 2020. “The Cost-Effectiveness of Using Pneumococcal Conjugate Vaccine (PCV13) versus Pneumococcal Polysaccharide Vaccine (PPSV23), in South African Adults.” PLoS ONE 15 (1): 1–49. doi:10.1371/journal.pone.0227945.